C.R. Bard, manufacturer of Avulta transvaginal mesh device, agreed to settle a woman’s claim that her implanted Avaulta transvaginal mesh caused her injury and complications that forcibly led to six surgeries. The agreement was reached before trial was to begin in West Virginia federal court.
The settlement terms were not released. In an e-mailed statement, Scott Lowry, a spokesman for the company said, that the agreement covered only this particular case, and not the thousands of other pending lawsuits against the company. This settlement is on the heels of a settlement last week that ordered Bard to pay $2 million in damages involving the same product.
“This is a large, complex litigation and Bard will consider each case based on the facts and merits,” Lowry said. “We will continue to vigorously defend against all other lawsuits involving Avaulta.”
Bard is currently facing more than 8,000 claims over Avaulta which has allegedly led to organ damage, painful sexual intercourse and more when the devices erode. Johnson & Johnson among other companies face similar complaints regarding their implants.
The Avaulta devices were pulled from the market last year when the FDA ordered all makers of the implants to study rates of organ damage, infection as well as pain during intercourse which was linked to their products.
Steve is the Managing Shareholder of Steven J. Klearman & Associates, a civil litigation law firm located in Reno, Nevada. He practices primarily in the areas of civil litigation and injury law, and has authored one of the definitive guides to Nevada civil law that is widely used by Nevada judges and attorneys, his book entitled Elements of Nevada Legal Theories.